MAIA Biotechnology, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
MAIA Biotechnology, Inc. (MAIA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $723.91 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-10
- MAIA Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $723.91K, a 9.79% decline year-over-year.
- MAIA Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $650.02K, a 74.99% increase year-over-year.
- MAIA Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $646.90K, a 42.05% increase year-over-year.
- MAIA Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $802.48K, a 93.86% increase year-over-year.
- MAIA Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $2.63M, a 37.59% increase from fiscal 2024.
- MAIA Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.91M, a 38.08% decline from fiscal 2023.
- MAIA Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.09M, a 33.19% increase from fiscal 2022.
- MAIA Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.32M, a 4.51% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $723.91K 10-Q · filed 2026-08-10 | $1.37M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $650.02K 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | $2.63M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $646.90K 10-Q · filed 2025-11-07 | $1.45M derived: sum of 2 quarters · filed 2026-08-10 | $1.82M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-06-30 | $802.48K 10-Q · filed 2026-08-10 | $1.17M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $371.47K 10-Q · filed 2026-08-10 | |||
| 2024-12-31 | $1.91M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $455.39K 10-Q · filed 2025-11-07 | $869.34K derived: sum of 2 quarters · filed 2025-11-07 | $1.22M derived: sum of 3 quarters · filed 2025-11-07 | |
| 2024-06-30 | $413.95K 10-Q · filed 2025-11-07 | $763.91K derived: sum of 2 quarters · filed 2025-11-07 | ||
| 2024-03-31 | $349.96K 10-Q · filed 2025-11-07 | |||
| 2023-12-31 | $3.09M 10-K · filed 2025-03-21 | |||
| 2023-09-30 | $570.92K 10-Q · filed 2024-11-12 | $1.19M derived: sum of 2 quarters · filed 2024-11-12 | $1.73M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $618.93K 10-Q · filed 2024-11-12 | $1.16M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $537.52K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $2.32M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $532.44K 10-Q · filed 2023-11-07 | $1.12M derived: sum of 2 quarters · filed 2023-11-07 | $1.83M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $584.77K 10-Q · filed 2023-11-07 | $1.30M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $713.33K 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $2.43M 10-K · filed 2023-03-24 | |||
| 2021-09-30 | $746.25K 10-Q/A · filed 2023-02-06 | $1.41M derived: sum of 2 quarters · filed 2023-02-06 | $1.81M derived: sum of 3 quarters · filed 2023-02-06 | |
| 2021-06-30 | $660.05K 10-Q/A · filed 2023-02-06 | $1.07M derived: sum of 2 quarters · filed 2023-02-06 | ||
| 2021-03-31 | $408.61K 10-Q/A · filed 2023-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |